Lincoln Pharmaceuticals Ltd

NSE: LINCOLN · BSE: 531633 · Pharmaceuticals & Biotechnology · 15 announcements

Share price: ₹564.70
Market cap: ₹1,131 Cr
Revenue (annual): ₹671.0 Cr
Net profit (annual): ₹87.89 Cr
P/E (TTM): 11.7×Sector 47.4×
Promoter holding: 49.78%+0.00% QoQ
FII holding: 4.60%Current quarter

Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.

Announcement type

All Other Announcement 4 Financial Results 3 Board Meeting Date 2 Results Correction 1 Management Change 1 Dividend 1 Debt & Borrowing 1 Annual Report 1 Annual General Meeting 1

Time

All time Last 1 week Last 1 month Last 2 months Last 3 months Last 6 months Last 1 year

3 announcements with these filters

13 Aug 2026 11:37 IST BSE

Financial Results

Lincoln Pharmaceuticals Q1 FY27 Results: Net Profit ₹36.2 Cr, Up 30.7% YoY

Lincoln Pharmaceuticals Ltd reported revenue from operations of ₹177.3 Cr (+15.1% YoY) and net profit of ₹36.2 Cr (+30.7% YoY) for Q1 FY27.

Key figure: Net profit ₹36.2 Cr · +30.7% YoY

Open full results → Read the filing ↗

28 May 2026 17:09 IST BSE

Financial Results

Lincoln Pharmaceuticals Q4 FY26 Results: Net Profit ₹11.6 Cr, Up 0.0% YoY

Lincoln Pharmaceuticals Ltd reported revenue from operations of ₹187.3 Cr (+11.4% YoY) and net profit of ₹11.6 Cr (+0.0% YoY) for Q4 FY26.

Key figure: Net profit ₹11.6 Cr · +0.0% YoY

Open full results → Read the filing ↗

28 May 2026 17:09 IST BSE

Financial Results

Lincoln Pharmaceuticals Financial Results

Lincoln Pharmaceuticals reported a consolidated net profit of ₹87.89 Crore for FY26. The board recommended an 18% dividend, signaling consistent shareholder returns and stable growth.

Value: ₹1.80 Cr

Read the filing ↗